Exhibit 99.1 argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China ● First-and-only approved FcRn antagonist for gMG patients by NMPA ● 68% of anti-AChR antibody positive gMG patients treated with VYVGART were responders (n=44/65) on the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale compared with 30% of patients treated with placebo (n=19/64) (p<0.0001) during the first treatment cycle in the Phase 3 ADAPT trial ● Zai Lab to s ...

Exhibit 99.2 argenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Generalized Myasthenia Gravis Regulated Information/Inside Information Amsterdam, the Netherlands—June 20, 2023—argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) approved VYVGAR ...

argenx SE (NASDAQ:ARGX) Q1 2023 Earnings Conference Call May 4, 2023 8:30 AM ET Company Participants Beth DelGiacco - Vice President of Corporate Communications and Investor Relations Tim Van Hauwermeiren - Chief Executive Officer Karl Gubitz - Chief Financial Officer Karen Massey - Chief Operating Officer Conference Call Participants Derek Archila - Wells Fargo Tazeen Ahmad - Bank of America Rajan Sharma - Goldman Sachs Yatin Suneja - Guggenheim Akash Tewari - Jefferies Thomas Smith - SVB Security Danielle ...

First Quarter 2023 Financial Results and Business Update May 4, 2023 Forward Looking Statements This presentation has been prepared by argenx se ("argenx" or the "company") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or the company or any director, employee, agent, or adviser of the company. This presentation does not purport to be all-inclusive or to contain ...

argenx • Together We Discover Corporate Presentation April 2023 Forward Looking Statements This presentation has been prepared by argenx se ("argenx" or the "company") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or the company or any director, employee, agent, or adviser of the company. This presentation does not purport to be all-inclusive or to contain all o ...

Exhibit 99.1 argenx Announces UK MHRA Approval of VYVGART for the Treatment of Generalized Myasthenia Gravis VYVGART is the first neonatal Fc receptor (FcRn) blocker approved in the UK for the treatment of adults living with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive 68% of anti-AChR antibody positive gMG patients treated with VYVGART were responders (n=44/65) on the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale compared with 30% of patient ...

Financial Position - As of December 31, 2022, cash and cash equivalents amounted to $800.7 million, while total capital was $4,316.5 million[978]. - The company has no financial debt, which mitigates interest rate risk on borrowings[978]. - The company raised approximately $662 million from a global offering of 2,333,334 ordinary shares, including ADSs[996]. - The net proceeds from the offering have been invested in cash and cash equivalents and current financial assets[997]. Interest Rate and Currency Risk - For the year ended December 31, 2022, a 25 basis points change in interest rates would have a positive/negative impact of $6.2 million[984]. - On December 31, 2022, a 10% increase/decrease in the EUR/USD exchange rate would have resulted in a negative/positive impact of $61.39 million[985]. Credit Risk Management - The company has adopted a policy to only deal with creditworthy counterparties, minimizing credit risk exposure[979]. - The provision for expected credit losses was not significant, as there have been no credit losses over the last three years[980]. - The company has a significant concentration of credit risk due to a limited number of collaboration and license partners[979]. Liquidity Risk Management - The company maintains liquidity risk management by monitoring cash flows and maintaining adequate reserves[982].

argenx SE (NASDAQ:ARGX) Q4 2022 Earnings Conference Call March 2, 2023 8:30 AM ET Company Participants Beth DelGiacco - VP Corporate Communications and IR Tim Van Hauwermeiren - CEO Karl Gubitz - CFO Keith Woods - COO Conference Call Participants Tazeen Ahmad - Bank of America Securities Rajan Sharma - Goldman Sachs Thomas Smith - SVB Securities Brendan Smith - Cowen Yatin Suneja - Guggenheim Partners Myles Minter - William Blair Manos Mastorakis - Deutsche Bank Alex Nackenoff - Raymond James Allison Bratze ...

Fourth Quarter and Full Year 2022 Financial Results and Business Update March 2, 2023 Forward Looking Statements This presentation has been prepared by argenx se ("argenx" or the "company") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or the company or any director, employee, agent, or adviser of the company. This presentation does not purport to be all-inclusi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECT ...